ArticleBMC microbiology2025
Synergetic effects of Ulva lactuca and Pterocladiella capillacea on the multidrug-resistant Klebsiella pneumoniae.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of the Antioxidative and Hepatoprotective Activity ofFoods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe potential of marine algae as a source of antibacterial chemicals has been very promising. Numerous bioactive compounds produced by these organisms can fight off harmful microorganisms. Two marine algae (Chlorophyta: Ulva lactuca, Rhodophyta: Pterocladiella capillacea) were screened for their antibacterial activity against distinct multidrug-resistant bacteria Klebsiella pneumoniae. This efficiency is ascribed to the bioactive substances found in these algae, which have the ability to stop the growth of this harmful bacteria. Pterocladiella capillacea is a viable target for the development of novel antibacterial medications since its chemicals function by interfering with bacterial processes.
resultsA mixture of (U. lactuca + P. capillacea. + Nitrofurantoin) increased the inhibition zone on K. pneumoniae by 100%. Our docking findings demonstrated that benzo[h]quinoline, 2, 4-dimethyl-, and 4, 4'-Bis [4-methyl-2-pyrimidylsulfamido] terephthalanilide have a high affinity (-10 and - 11 respectively) to dock with the cell wall proteins of Klebsiella pneumoniae. It can cause cell lysis and death by interfering with the integrity of bacterial cell walls. Furthermore, it may disrupt DNA replication and vital bacterial enzymes. The molecule 4, 4'-Bis [4-methyl-2-pyrimidylsulfamido] terephthalanilide is a member of the sulfonamide class, which is well-known for its broad-spectrum antibacterial properties. This compound's capacity to prevent bacteria from synthesizing folic acid is the main source of its antibacterial action. Bacterial cell division and DNA synthesis depend on folic acid. The substance successfully stops bacterial growth and multiplication by blocking this pathway.
conclusionThese two substances are interesting candidates for the development of novel antimicrobial drugs due to their efficacy against strains of bacteria that are resistant to antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.